Literature DB >> 31542979

An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Alyssa Bottrell1, Yong Hong Meng1, Abdo J Najy1, Newton Hurst1, Seongho Kim2, Chong Jai Kim1, Eun-Sook Kim3, Aree Moon3, Eun Joo Kim4, So Yeon Park4, Hyeong-Reh Choi Kim1.   

Abstract

Despite strong evidence for the involvement of PDGF signaling in breast cancer, little is known about the PDGF ligand responsible for PDGFR activation during breast cancer progression. Here, we found PDGF-C to be highly expressed in breast carcinoma cell lines. Immunohistochemical analysis of invasive breast cancer revealed an association between increased PDGF-C expression and lymph node metastases, Ki-67 proliferation index, and poor disease-free survival. We also identified a PDGF-C splice variant encoding truncated PDGF-C (t-PDGF-C) isoform lacking the signal peptide and the N-terminal CUB domain. While t-PDGF C homodimer is retained intracellularly, it can be secreted as a heterodimer with full-length PDGF-C (FL-PDGF-C). PDGF-C downregulation reduced anchorage-independent growth and matrigel invasion of MDA-MB-231 cells. Conversely, ectopic expression of t-PDGF-C enhanced phenotypic transformation and invasion in BT-549 cells expressing endogenous FL-PDGF-C. The present study provides new insights into the functional significance of PDGF-C and its splice variant in human breast cancer.

Entities:  

Keywords:  Breast cancer; growth factors: structure and function; oncogenic activity; prognostic marker; tumor cell invasion

Mesh:

Substances:

Year:  2019        PMID: 31542979      PMCID: PMC6872946          DOI: 10.1080/08977194.2019.1662415

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  48 in total

1.  Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.

Authors:  J M Schafer; E S Lee; R M O'Regan; K Yao; V C Jordan
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

2.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

3.  Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines.

Authors:  Jeffrey P Zwerner; William A May
Journal:  Oncogene       Date:  2002-05-30       Impact factor: 9.867

4.  Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor.

Authors:  D G Gilbertson; M E Duff; J W West; J D Kelly; P O Sheppard; P D Hofstrand; Z Gao; K Shoemaker; T R Bukowski; M Moore; A L Feldhaus; J M Humes; T E Palmer; C E Hart
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

5.  Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Authors:  Gert G Van den Eynden; Steven J Van Laere; Ilse Van der Auwera; Sofia D Merajver; Eric A Van Marck; Peter van Dam; Peter B Vermeulen; Luc Y Dirix; Kenneth L van Golen
Journal:  Breast Cancer Res Treat       Date:  2005-10-22       Impact factor: 4.872

6.  Schwannoma-derived growth factor must be transported into the nucleus to exert its mitogenic activity.

Authors:  H Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Alterations in beta-catenin phosphorylation and plakoglobin expression in human breast cancer cells.

Authors:  C L Sommers; E P Gelmann; R Kemler; P Cowin; S W Byers
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

8.  Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor.

Authors:  R F Doolittle; M W Hunkapiller; L E Hood; S G Devare; K C Robbins; S A Aaronson; H N Antoniades
Journal:  Science       Date:  1983-07-15       Impact factor: 47.728

9.  Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

10.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

View more
  4 in total

1.  Glycosylation at Asn254 Is Required for the Activation of the PDGF-C Protein.

Authors:  Wenjie Hu; Ruting Zhang; Wei Chen; Dongyue Lin; Kun Wei; Jiahui Li; Bo Zhang; Xuri Li; Zhongshu Tang
Journal:  Front Mol Biosci       Date:  2021-05-24

2.  Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.

Authors:  Sarah Förster; Maryam Givehchi; Katja Nitschke; Thomas Mayr; Kerstin Kilian; Samikshan Dutta; Kaustubh Datta; Philipp Nuhn; Zoran Popovic; Michael H Muders; Philipp Erben
Journal:  Genes (Basel)       Date:  2021-04-09       Impact factor: 4.096

Review 3.  Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.

Authors:  Nehad M Ayoub; Sara K Jaradat; Kamal M Al-Shami; Amer E Alkhalifa
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

4.  Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients.

Authors:  Dimitrios Balalis; Dimitrios Tsakogiannis; Eleni Kalogera; Stefania Kokkali; Elli Tripodaki; Alexandros Ardavanis; Dimitrios Manatakis; Dionysios Dimas; Nektarios Koufopoulos; Florentia Fostira; Dimitrios Korkolis; Ioannis Misitzis; Nikolaos Vassos; Chara Spiliopoulou; Dimitrios Vlachodimitropoulos; Garyfalia Bletsa; Nikolaos Arkadopoulos
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.